{
  "abstract": "Background Diazoxide is the only oral treatment used in the management of Congenital Hyperinsulinism (CHI). While the liquid formulation (Proglycem®) is commonly prescribed, it poses challenges due to high cost and limited availability in primary care. Most patients under our care receive prescriptions directly from Great Ormond Street Hospital (GOSH), creating a dependency on tertiary services.Aim To transition eligible patients (aged ≥7 years) from the liquid to tablet formulation, improving access, reducing costs, and supporting independent prescribing in primary care.Methods Identified eligible patients currently receiving diazoxide liquid. The CHI multidisciplinary team (MDT) to develop a standardized dose conversion guide. Develop educational materials for patients and families to facilitate the transition. Additional support from play specialists and psychology to be offered where appropriate. Collaborated with the pharmacy to ensure a consistent supply of diazoxide tablets and developed a contingency plan to address potential shortagesResults An audit identified 19 eligible patients. To date, 14 have successfully transitioned to Diazoxide tablets. Patient and caregiver education materials, including tablet-swallowing training, have been developed and implemented. Initial results indicate stable glycaemic control, absence of adverse events, and enhanced prescribing efficiency. All participants indicated a preference for the tablets, citing the unpleasant taste of the liquid formulation. A clear financial benefit was achieved as a 50mg Diazoxide tablet is 10 times cheaper than 50mg Proglycem® Diazoxide liquid.Conclusion A structured transition from liquid to tablet diazoxide formulation illustrates a safe, effective, and sustainable strategy. Benefits for the child include improved palatability, greater independence, and ease of travel. Cost savings were achieved without compromising patient care. Diazoxide is not a pass-through (NHS Commissioner) funded drug, any reductions in spend directly deliver a financial benefit to the Trust. This strategy of transitioning from liquid to tablets potentially could reduce the dependency of a tertiary centre.",
  "authors": [
    {
      "affiliations": [
        "Great Ormond Street Hospital for Children NHS Foundation Trust, UK"
      ],
      "name": "Kate Morgan"
    },
    {
      "affiliations": [
        "Great Ormond Street Hospital for Children NHS Foundation Trust, UK"
      ],
      "name": "Clare Gilbert"
    },
    {
      "affiliations": [
        "Great Ormond Street Hospital for Children NHS Foundation Trust, UK"
      ],
      "name": "Niamh Harman"
    },
    {
      "affiliations": [
        "Great Ormond Street Hospital for Children NHS Foundation Trust, UK"
      ],
      "name": "Sinead McGlackern-Byrne"
    },
    {
      "affiliations": [
        "Great Ormond Street Hospital for Children NHS Foundation Trust, UK"
      ],
      "name": "Antonia Dastamani"
    }
  ],
  "title": "51 Transition patients with Congenital Hyperinsulinism from Proglycem® Diazoxide liquid to Diazoxide tablets",
  "uid": "da73fa52-0ae6-5c87-9c1d-0a84a41fc746"
}